A Phase 1/2, Multicenter, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KK2430 in Participants With Hematologic Neoplasms

Inclusion Criteria: * Participants must be at least 18 years of age at the time of signing the informed consent. * At least 1 measurable diseases based on CT scan or MRI * Renal function values * Participants who have an ECOG PS score of 0, 1 or 2. * Be willing to provide a fresh tissue taken at current relapse at screening period. * Meet laboratory values at Screening i.e., ANC, Platelets, Corrected serum calcium, AST and ALT, Total bilirubin etc * Contraceptive use by \[men and women\] should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. * Women of childbearing potential and fertile men must agree to use highly effective contraceptive methods • At least 1 measurable diseases based on CT scan or MRI * Capable of giving signed informed consent * Health Information Access: Capable of providing access to personal health information via HIPAA authorization (US only). * Legal Status: Not under any administrative or legal supervision or institutionalization due to regulatory or juridical order. Exclusion Criteria: * Medical Conditions * History of prior allogenic transplant. * Presence of Grade 2 peripheral neuropathy with pain. * Impaired cardiac function or clinically significant cardiac disease at Screening * Known active CNS involvement or clinical signs of meningeal involvement. * Evidence of HIV infection. * Active chronic HBV/HCV infection, * Participants with positive anti-HBc must have a negative HBV-DNA quantification test result to be enrolled. * Receipt of any anti-tumor therapy within three weeks or at least five half-lives prior to the Screening visit, whichever is shorter. * Toxicities from prior anticancer therapies that have not resolved to Grade 1 or less except for abnormal clinical values alopecia and peripheral neuropathy (participants with Grade 1 or 2 neuropathy without pain are eligible for enrollment). * Use of systemic corticosteroids exceeding 10 mg/day of prednisone or equivalent within 14 days prior to the first dose